|
Roche, PerkinElmer ink new supply
agreement
08-18-2011
EDIT CONNECT
SHARING OPTIONS:
MADISON, Wis. & WALTHAM, Mass.—Roche and PerkinElmer
have announced that they have formed a new supply agreement for the
distribution of the NimbleGen CGX mircroarray workflow,
for use in
constitutional disease research. The agreement, which goes into effect as of
January 2012, states that PerkinElmer will take over
responsibility for the
sale, service and support of the CGX array workflow for most countries outside
of the United States. Roche, in turn, will
maintain responsibility for selling
the workflow in the United States and other select markets. The new agreement
is a continuation of Roche and
PerkinElmer's business relationship, which began
in 2009 when the two worked on the development of a comprehensive cytogenetics
array workflow.
Financial terms of the agreement were not disclosed.
"We are delighted to continue our collaboration
with Roche
in helping to bring the benefits of a proven cytogenetics-based solution to
researchers of new diagnostics outside of the U.S.," Jim
Corbett, President,
Diagnostics at PerkinElmer, said in a press release about the agreement. "We
look forward to providing these diagnostics
researchers with high-resolution,
scalable and easy to use workflows to help them unlock DNA-based complexities
of critical disease states."
The NimbleGEN CGX array workflow utilizes Roche's advanced
microarray technologies and combines them
with the cytogenetic-focused array
design and analysis software developed by Signature Genomics, which PerkinElmer
acquired in May of last year.
Signature Genomics was the first laboratory to
offer microarray-based cytogenetic testing in the United States, and its design
of the NimbleGen CGX
array design was based on the analysis of more than 50,000
cytogenetic samples in order to provide sufficient coverage of cytogenetically
relevant
regions.
The combined workflow represents a comprehensive microarray
solution for discovering and
analyzing copy number variations that are
associated with various constitutional disorders for the cytogenetics research
market. It consists of
NimbleGen CGX microarrays, reagent kits, the NimbleGen
Hybridization Systems and Signature Genomics Genoglyphix software for data
analysis. The
NimbleGen CGX arrays come in 3-, 6- and 12-plex formats to
fulfill a variety of throughput requirements.
"This collaboration provides cytogenetics laboratories an
array workflow with robust data, a quick and easy workflow, and powerful
analysis
tools," said Frank Pitzer, CEO of Roche NimbleGen, in a press release.
"PerkinElmer's global experience in the genetic screening market and expertise
in the field of cytogenetics is an ideal match for Roche NimbleGen's innovative
array technologies."
SOURCE: PerkinElmer press release Code: E08181101 Back |
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|